Sabuwar Dabaru Mai Tallafawa Yana Inganta Tsaro da Ingancin Maganin CAR-T a Cutar Cutar Leukemia Mai Tsanani ta B Cell
Beijing, China – 23 ga Yuli, 2024 – A wani ci gaba mai ban mamaki, Asibitin Lu Daopei, tare da haɗin gwiwar Hebei Senlang Biotechnology, sun bayyana sakamako mai kyau daga sabon bincikensu kan maganin ƙwayoyin cuta na chimeric antigen receptor T (CAR-T). Wannan binciken, wanda ya mayar da hankali kan inganci da amincin ƙwayoyin CAR-T waɗanda aka ƙera tare da masu haɓaka daban-daban, yana nuna babban ci gaba a cikin maganin cutar sankarar jini ta B cell leukemia (B-ALL) da ta sake dawowa ko kuma ta sake yin illa.
Binciken, mai taken "Amfani da Mai Tallafawa Yana Daidaita Yawan Kwayoyin CAR Na Iya Daidaita Tsarin Kwayoyin CAR-T A Vivo," ya binciki yadda zaɓin mai tallatawa zai iya yin tasiri ga aikin ƙwayoyin CAR-T. Masu bincike Jin-Yuan Ho, Lin Wang, Ying Liu, Min Ba, Junfang Yang, Xian Zhang, Dandan Chen, Peihua Lu, da Jianqiang Li daga Hebei Senlang Biotechnology da Asibitin Lu Daopei ne suka jagoranci wannan binciken.
Binciken da suka yi ya nuna cewa amfani da MND (myeloproliferative sarcoma virus MPSV enhancer, negative control region NCR deletion, d1587rev primer binding site replacement) promoter a cikin ƙwayoyin CAR-T yana haifar da ƙarancin yawan ƙwayoyin CAR, wanda hakan ke rage samar da cytokine. Wannan yana da mahimmanci saboda yana taimakawa wajen rage mummunan illolin da galibi ke tattare da maganin CAR-T, kamar su cutar sakin cytokine (CRS) da kuma cutar encephalopathy da ke da alaƙa da ƙwayoyin CAR-T (CRES).
Gwajin asibiti, wanda aka yi wa rijista a ƙarƙashin lambar NCT03840317 ta ClinicalTrials.gov, ya haɗa da marasa lafiya 14 da aka raba zuwa ƙungiyoyi biyu: ɗaya yana karɓar ƙwayoyin CAR-T da ke aiki da MND, ɗayan kuma yana karɓar ƙwayoyin CAR-T da ke aiki da EF1A. Abin mamaki, duk marasa lafiya da aka yi wa magani da ƙwayoyin CAR-T da ke aiki da MND sun sami cikakkiyar sassauci, inda yawancinsu suka nuna ƙarancin yanayin rashin lafiya bayan wata na farko. Binciken ya kuma ba da rahoton ƙarancin yawan CRS da CRES masu tsanani a cikin marasa lafiya da aka yi wa magani da ƙwayoyin CAR-T da ke aiki da MND idan aka kwatanta da waɗanda aka yi wa magani da ƙwayoyin EF1A.
Dr. Peihua Lu daga Asibitin Lu Daopei ya bayyana kyakkyawan fata game da yuwuwar wannan sabuwar hanyar, yana mai cewa, "Haɗin gwiwarmu da Hebei Senlang Biotechnology ya samar da muhimman bayanai game da inganta maganin ƙwayoyin CAR-T. Ta hanyar daidaita mai haɓaka, za mu iya haɓaka yanayin aminci na maganin yayin da muke ci gaba da ingancinsa. Wannan babban ci gaba ne wajen sa maganin CAR-T ya fi sauƙi kuma ya zama mai jurewa ga marasa lafiya."
An tallafawa binciken ne daga tallafin Gidauniyar Kimiyyar Halitta ta Lardin Hebei da Ma'aikatar Kimiyya da Fasaha ta Lardin Hebei. Yana nuna mahimmancin zaɓar masu haɓaka maganin ƙwayoyin cuta na CAR-T kuma yana buɗe sabbin hanyoyi don aminci da inganci. Maganin Ciwon dajis.